Biogen Halts Plans to Develop Tysabri for Stroke After Phase IIb Trial Flop Post author:Sam Post published:February 6, 2018 Post category:BioPharma Natalizumab did not demonstrate improvement in clinical outcomes compared to placebo. Source: BioSpace You Might Also Like Otsuka Pharma Believes in Akebia, Commits Another $865 Million to Expand Anemia Deal April 25, 2017 Tesaro To Announce Second-Quarter 2017 Financial Results On August 8, 2017 July 25, 2017 79 Employees Affected as Novartis Plans Shut Down of UK Site December 4, 2017
